Skip to main content
رجوع
Watch Compare

Ginkgo Bioworks Holdings, Inc.

جودة البيانات: 100%
مُدرج أيضًا باسم DNABW NYSE
DNA
NYSE Manufacturing Chemicals
KWD 6.38
▼ KWD 0.51 (-7.34%)
القيمة السوقية: 394.77 M
السعر
KWD 6.38
القيمة السوقية
394.77 M
نطاق اليوم
KWD 6.24 — KWD 6.73
نطاق 52 أسبوعًا
KWD 5.37 — KWD 17.58
حجم التداول
682,741
فتح KWD 6.67
متوسط 50 يوم / 200 يوم
KWD 7.91
19.43% below
متوسط 50 يوم / 200 يوم
KWD 10.29
38.03% below

Quick Summary

النقاط الرئيسية

Revenue declined -14.19% annually over 5 years
Negative free cash flow of -178.72 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 10.87%
Capital efficient — spends only 4.50% of revenue on capex

النمو

Revenue Growth (5Y)
-14.19%
أقل من متوسط القطاع (1.82%)
Revenue (1Y)-25.06%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-53.34%
أعلى من متوسط القطاع (-53.41%)
ROIC-22.56%
Net Margin-183.81%
Op. Margin-185.29%

الأمان

Debt / Equity
N/A
Current Ratio4.39
Interest CoverageN/A

التقييم

PE (TTM)
-1.26
أعلى من متوسط القطاع (-1.48)
P/B Ratio0.71
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -1.3 -1.5
P/B 0.7 1.6
ROE % -53.3 -53.4
Net Margin % -183.8 -41.5
Rev Growth 5Y % -14.2 1.8
D/E — 0.3

ETFs Holding This Stock

NXTE logo NXTE AXS Green Alpha ETF
0.09% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0.02% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -25.06% Revenue Growth (3Y) -17.74%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -14.19% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 170.16 M Net Income (TTM) -312.76 M
ROE -53.34% ROA -25.85%
Gross Margin N/A Operating Margin -185.29%
Net Margin -183.81% Free Cash Flow (TTM) -178.72 M
ROIC -22.56% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4.39
Interest Coverage N/A Asset Turnover 0.14
Working Capital 390.80 M Tangible Book Value 498.26 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.26 Forward P/E N/A
P/B Ratio 0.71 P/S Ratio 2.32
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -45.27%
Market Cap 394.77 M Enterprise Value 283.70 M
Per Share
EPS (Diluted TTM) -5.64 Revenue / Share 2.75
FCF / Share -2.89 OCF / Share -2.76
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 4.50% FCF Conversion 57.14%
SBC-Adj. FCF -253.10 M Growth Momentum -10.87

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 170.16 M 227.04 M 251.46 M 477.71 M 313.84 M
Net Income -312.76 M -547.03 M -892.87 M -2.10 B -1.83 B
EPS (Diluted) -5.64 -10.54 -0.46 -1.25 -1.39
Gross Profit — — — — —
Operating Income -315.28 M -559.76 M -864.41 M -2.21 B -1.83 B
EBITDA — — — — —
R&D Expenses 243.77 M 424.06 M 580.62 M 1.05 B 1.15 B
SG&A Expenses — — — — —
D&A 58.99 M 63.02 M 70.51 M 42.55 M 29.08 M
Interest Expense 0.0 94,000.0 93,000.0 106,000.0 2.37 M
Income Tax -837,000.0 -479,000.0 -71,000.0 -15.03 M -1.48 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.12 B 1.38 B 1.67 B 2.54 B 2.07 B
Total Liabilities 611.11 M 661.39 M 568.19 M 803.04 M 503.61 M
Shareholders' Equity 508.59 M 716.06 M 1.10 B 1.74 B 1.51 B
Total Debt — — — — —
Cash & Equivalents 167.20 M 561.57 M 944.07 M 1.32 B 1.55 B
Current Assets 471.84 M 602.74 M 1.00 B 1.45 B 1.72 B
Current Liabilities 95.97 M 107.27 M 163.86 M 172.96 M 134.76 M